Translation of "Chronische niereninsuffizienz" in English

The following breeds are prone to chronic renal failure:

The renal failure may according to the invention also be chronic renal failure.

The terminal stage of chronic renal failure is uremia.

Chronic renal insufficiency is characterized by a slow progressive loss of the renal function.

The final stage of chronic kidney disease is known as chronic renal failure.

Chronic renal insufficiency is diagnosed with blood and urine tests.

Chronic renal insufficiency leads to metabolic disorders in the bones, which in turn stimulates production of the parathyroid hormone.

Before instituting treatment with somatropin for growth retardation secondary to chronic renal insufficiency, children should have been followed for one year to verify growth disturbance.

Risk factors for TLS include high tumour burden, pre-existing chronic renal insufficiency, oliguria, dehydration, hypotension, and acidic urine.

In most cases risk factors have been identified, such as pre-existing renal insufficiency, diabetes mellitus, hypovolaemia, overweight, concomitant nephrotoxic medicinal products or age over 65.

If you have chronic renal failure there is an increased risk of serious problems with your heart or blood vessels (cardiovascular events) if your haemoglobin is kept too high.

Illnesses and pathological conditions which are associated with a low cGMP level or in which an increase in the cGMP level is desired and for whose therapy and prophylaxis compounds of the formula I can be employed are, for example, cardiovascular disorders such as endothelial dysfunction, diastolic dysfunction, atherosclerosis, high blood pressure, stable and unstable angina pectoris, thromboses, restenoses, myocardial infarcts, strokes, cardiac insufficiency or pulmonary hypertension, or, for example, erectile dysfunction, bronchial asthma, chronic renal insufficiency and diabetes.

Chronic renal insufficiency develops slowly and may cause only a few symptoms or unspecific symptoms such as fatigue and loss of performance for a long period of time.

It is essential to detect the cause of the chronic renal insufficiency to be able understand and treat the disease.

Diseases and pathological conditions which are associated with a low cGMP level or in which an increase in the cGMP level is desired and for whose therapy and prophylaxis compounds of the formula I can be employed are, for example, cardiovascular conditions such as endothelial dysfunction, diastolic dysfunction, atherosclerosis, high blood pressure, stable and unstable angina pectoris, thromboses, restenoses, myocardial infarcts, strokes, cardiac insufficiency or pulmonary hypertension, or, for example, erectile dysfunction, bronchial asthma, chronic renal insufficiency and diabetes.

The chronic renal failure results from removal of the right kidney and ligation of the segmental arteries which supply the upper and lower renal pole of the left kidney.

Diseases and pathological conditions which are associated with a low cGMP level or in which an increase or normalization in the cGMP level is desired and for whose therapy and prophylaxis compounds of the formula I can be employed are, for example, cardiovascular disorders such as endothelial dysfunction, diastolic dysfunction, atherosclerosis, high blood pressure, stable and unstable angina pectoris, thromboses, restenoses, myocardial infarct, strokes, cardiac insufficiency or pulmonary hypertension, or, for example, erectile dysfunction, bronchial asthma, chronic renal insufficiency and diabetes.

Disorders with uncontrolled apoptosis are, for example, infarct, stroke, transplants, autoimmune disorders, inflammations, neurodegeneration, myoma, muscular atrophy, muscular dystrophy, cachexia, systemic inflammation response syndrome (SIRS), adult respiratory distress syndrome (ARDS), cerebral malaria, pulmonary sarcosidosis, enteritis, chronic pneumonia, reperfusion damage, scar formation, burn damage, acquired immune deficiency syndrome (AIDS), cancer, disorders with increased protein loss, chronic renal insufficiency or hypertrophic disorders.

The phosphate from the group including the small-molecular water-soluble uremia toxins is subject to a permanent control, since the chronic renal insufficiency leads to a hyperphospatemia and is a decisive risk factor for mortality.

As chronic renal insufficiency cannot usually be reversed, the treatment focuses on slowing down the progression of the disease and retaining the residual kidney function.

In the following years, GH continued to gain approval for the treatment of specific clinical conditions causing short stature and other complications related to lifelong GHD such as Prader-Willi syndrome, short stature caused by chronic renal insufficiency, Turner syndrome, idiopathic short stature, and intrauterine growth retardation.

While chronic renal failure cannot be reversed or cured, treatment and management aimed at reducing the contributing factors and symptoms can slow its progression.

This so-called microangiopathy can manifest itself as chronic renal failure (diabetic nephropathy), nerve damage (diabetic neuropathy), or blindness (diabetic retinopathy).